甲基化抑制剂对CEM细胞EphB4基因表达及细胞增殖与凋亡的影响

摘要
图/表
参考文献(12)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (1259 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的：探讨甲基化抑制剂5-氮杂-2'脱氧胞苷（5-aza-2'-deoxycytidine，5aza-CdR）对人急性淋巴细胞白血病细胞株CEM中抑癌基因EphB4的转录调控作用及对CEM细胞增殖凋亡的生物学影响，为寻找肿瘤治疗新靶点提供实验依据。方法：采用亚硫酸氢盐修饰后测序法检测EphB4基因甲基化水平，荧光定量PCR法(Q-PCR)和Western blot方法检测5-aza-CdR处理前后EphB4基因mRNA及蛋白表达水平；MTS法检测不同剂量(1.0、2.5、5.0 μmol/L) 的5-aza-CdR作用于CEM细胞0 h、24 h、48 h、72 h、96 h对CEM细胞存活率的影响，流式细胞仪分析5-aza-CdR作用96 h对CEM细胞周期及凋亡的影响。结果：CEM细胞中存在EphB4基因的甲基化，甲基化水平为31.4%；不同浓度5-aza-CdR作用后CEM细胞甲基化水平均下降。5-aza-CdR作用使CEM细胞中EphB4 基因的mRNA和蛋白表达上升；5-aza-CdR明显抑制CEM细胞增殖，并与药物浓度及作用时间呈正相关。5-aza-CdR处理 96 h后，早期凋亡由4.1%上升为24.8%。用药96 h后，CEM细胞G1期由62.4% 降至46.8%，G2期由2.1%升至16.2%，细胞阻滞于G2期。结论：特异性甲基化转移酶抑制剂5-aza-CdR能使CEM细胞中沉默的EphB4基因重新表达，并可抑制白血病细胞增殖和诱导其凋亡。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李玉华
	文飞球
	陈亦欣
	李长钢
	张朝霞
	陈小文
	李博

关键词 ： 5-氮杂-2'-脱氧胞苷, EphB4基因, 增殖, 凋亡, CEM细胞

Abstract：OBJECTIVE: To study the regulation of methylation inhibitor 5-aza-2'-deoxycytidine on transcription of EphB4 gene and effects on the proliferation and apoptosis of human acute lymphocyte leukemia cell line CEM.MethodsBisulfite sequencing PCR was used to detect CpG island methylation density in EphB4 promoter. The expression of EphB4 mRNA and protein was determined by Q-PCR and Western blot. MTS assay and flow cytometry were used to detect the apoptosis of CEM cells after treatment with different concentrations of 5-aza-2'-deoxycytidine (1.0, 2.5 and 5 μmol/L).ResultsMethylation of EphB4 gene promoter was detected in CEM cells (31.4%). The methylation level of EphB4 gene was down-regulated after treatment with various concentrations of 5-aza-2'-deoxycytidine. The EphB4 mRNA and protein expression in CEM cells increased after 5-aza-2'-deoxycytidine treatment. 5-Aza-2'-deoxycytidine significantly inhibited the cell growth in dose and time dependent manners. Early apoptosis rates of CEM cells increased from 4.1% to 24.8% 96 hrs after 5-aza-2'-deoxycytidine treatment. CEM cells in G1 phase decreased from 62.4% to 46.8%, cells in G2 phase increased from 2.1% to 16.2%, and CEM cells were arrested in G2 phase after treatment with 5 μmol/L 5-aza-2'-deoxycytidine for 96 hrs. CONCLUSIONS: 5-Aza-2'-deoxycytidine, an inhibitor of specific methylation transferase, can induce expression of the silent EphB4 gene in CEM cells, inhibit the proliferation of leukemia cells and induce cell apoptosis.

Key words： 5-Aza-2'-deoxycytidine EphB4 gene Proliferation Apotosis CEM cell

PACS:

R-33

引用本文:

李玉华,文飞球,陈亦欣等. 甲基化抑制剂对CEM细胞EphB4基因表达及细胞增殖与凋亡的影响[J]. 中国当代儿科杂志, 2012, 14(3): 205-209.

LI Yu-Hua,WEN Fei-Qiu,CHEN Yi-Xin et al. Effect of methylation inhibitor on EphB4 gene expression, proliferation and apoptosis in CEM cells[J]. CJCP, 2012, 14(3): 205-209.

链接本文:

http://www.zgddek.com/CN/ 或 http://www.zgddek.com/CN/Y2012/V14/I3/205

	［1］李玉华，文飞球. DNA甲基化与儿童白血病的临床研究进展［J］. 中国当代儿科杂志，2011，13(2): 174-176.
	［2］Batlle E, Bacani J, Begthel H, Jonkeer S, Gregorieff A, van de Born M, et al. EphB receptor activity suppresses colorectal cancer progression［J］. Nature, 2005, 435(7045): 1126-1130.
	［3］Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway［J］. Nat Cell Biol, 2006, 8(8): 815-825.
	［4］Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, et al. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors［J］. Cancer Res, 2005, 65(22): 10170-10173.
	［5］Davalos V, Dopeso H, Casta~no J, Wilson AJ, Vilardell F, Romero-Gimenez J, et al. EPHB4 and survival of colorectal cancer patients［J］. Cancer Res, 2006, 66(18): 8943-8948.
	［6］Fox BP, Kandpal RP. Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR［J］. Biochem Biophys Res Commun, 2006, 340(1): 268-276.
	［7］Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC, et al. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin［J］. Cancer Res, 2006, 66(14): 7050-7058.
	［8］Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer［J］. Nat Genet, 2004, 36(9): 979-983.
	［9］Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia［J］. Leukemia, 2008, 22(8): 1529-1538.
	［10］Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy［J］. Nature, 2004, 429(6990): 457-463.
	［11］Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies［J］. Leuk Lymphoma, 2007, 48(8): 1472-1481.
	［12］Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, et al. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia［J］. Blood, 2010, 115(12): 2412-2419.